ROADMAPS DETERMINE GAVI’S LONG-TERM MARKET AMBITION FOR EACH VACCINE OR IMMUNISATION PRODUCT. THEY PRESENT BOTH A SHORT- AND LONG-TERM VIEW OF HOW WE WOULD LIKE THE MARKET TO EVOLVE FOR A PARTICULAR VACCINE OR PRODUCT, IDENTIFY MECHANISMS THAT CAN HELP TO INFLUENCE IT, AND INFORM PROCUREMENT DECISIONS.

Previously, Gavi’s roadmaps primarily served to set a precedent for understanding market behaviour and foster transparency of information between core partners. Per MS 5.0, supply and procurement roadmaps now additionally promote long-term views of individual vaccine markets, while also enhancing process efficiencies and synergies.

Vials with the Mosquirix malaria vaccine at the Kisumu Regional Vaccine Depot. Gavi/2021/White Rhino Films-Lameck Orina

I. VACCINE ROADMAPS

See all vaccine roadmaps

COVID-19 vaccine roadmap: public summary 2022

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, leading to the ongoing pandemic. This document is the public summary of the market shaping roadmap for COVID-19 vaccines.

Ebola vaccine roadmap: public summary (2017)

In 2014, Gavi has committed to purchase Ebola vaccine for a global stockpile as soon as a safe, effective vaccine is recommended for use by the World Health Organization. This document is the public summary of the supply and procurement roadmap for Ebola vaccine.

Human papillomavirus vaccine roadmap: public summary (2017)

Gavi opened a funding window for human papillomavirus (HPV) vaccines in 2012. The public summary of the HPV vaccine roadmap gives an overview of the market dynamics for this vaccine.

Japanese encephalitis vaccine roadmap: public summary (2018)

At its November 2013 Board meeting, the Vaccine Alliance opened a funding window for Japanese encephalitis (JE) catch-up campaigns in endemic countries. Download the public summary of the supply and procurement roadmap to learn more about Gavi’s market shaping objectives for the JE vaccine market.

Malaria vaccine roadmap: public summary (2022)

Gavi Board approved a funding window for malaria vaccines in December 2021 to support the use of malaria vaccines in routine immunisation programmes. This document is the public summary of the market shaping roadmap for malaria vaccines.

Measles-rubella vaccine roadmap: public summary (2017)

Gavi’s engagement on measles dates to 2004 and rubella support began in 2011 through the measles-rubella (MR) vaccine. By the end of 2016, Gavi had supported 50 countries with MR programmes. This public summary of the supply and procurement roadmap describes the market, and outlines Gavi’s market shaping ambitions for MR vaccines.

Meningococcal vaccine roadmap: public summary (2015)

Gavi supports meningococcal vaccines for use in campaigns and routine immunisation in endemic countries in Africa. This document is the public summary of the supply and procurement roadmap for meningococcal vaccine.

Meningococcal vaccines for outbreak response roadmap: public summary (2019)

In 2008, the Gavi Board approved the strategy to eliminate serogroup A meningococcal meningitis and in 2016, the Gavi Board approved the emergency stockpile commitment to be extended indefinitely. This document is the public summary of the supply and procurement roadmap for meningococcal vaccines for outbreak response.

Oral cholera vaccine roadmap: public summary (2023)

Gavi has been engaged in cholera vaccination since 2014 through the funding and support of the global stockpile of cholera vaccines. This document is the public summary of the  market shaping roadmap for oral cholera vaccines.

Pentavalent, IPV, Hexavalent and DTwP-containing boosters during 2nd year of life Roadmap: public summary (2020)

In 2013, the Gavi Board decided to fund the introduction of inactivated polio vaccine (IPV) in all Gavi-supported countries, and in 2018, it approved support for DTwP-containing boosters and in-principle support for Hexavalent which combines Pentavalent (DTwP-HepB-Hib) and IPV antigens. This document is the public summary of the supply and procurement roadmap for these four interrelated markets.

Pneumococcal vaccine roadmap: public summary (2022)

Gavi has supported routine introductions with pneumococcal vaccine since 2009. Find out more about the pneumococcal vaccine market, and Gavi’s approach to shaping it, in the public summary of the vaccine roadmap.

Rotavirus vaccine roadmap: public summary (2022)

Rotavirus is the leading cause of severe diarrhoea in children under five years of age worldwide. This document is the public summary of the supply and procurement roadmap for rotavirus vaccine.

Typhoid conjugate vaccine roadmap: public summary (2022)

Gavi opened a funding window for typhoid conjugate vaccine in November 2017, supporting catch-up campaigns and co-financing of the vaccine use in routine immunisation programmes. This document is the public summary of the supply and procurement roadmap for TCV.

Yellow fever laboratory diagnostic capacity: public summary (2020)

In November 2018, the Gavi Board approved allocation of USD 13.5 million as funding to support a three-year multi-faceted programme to improve yellow fever laboratory capacity in Africa during 2019-2021. This document is the public summary of the supply and procurement roadmap for yellow fever laboratory diagnostics for routine and outbreak yellow fever testing.

Yellow fever vaccine roadmap: public summary (2017)

Gavi has been engaged in yellow fever (YF) vaccination since 2001 in support of WHO efforts to control the disease. This document is the public summary of the supply and procurement roadmap for yellow fever vaccine.

II. COLD CHAIN EQUIPMENT ROADMAPS

Cold chain equipment - Gavi/2018/Simon Davis

See all cold chain equipment roadmaps

Ice-lined (ILR) and Solar Direct Drive (SDD) refrigerators/freezers: public summary (2021)

Gavi established the Cold Chain Equipment Optimisation Platform (CCEOP) in June 2015 as a strategic and targeted approach to address the challenges of improving the vaccine cold chain with higher-performing equipment and meeting unmet country needs. This document provides a public summary of the market shaping roadmap for two CCE product categories: Ice-lined (ILR) & Solar Direct Drive (SDD) refrigerators/ freezers.

Gavi/IVAC/2018/Amanda Mustard

III. DIAGNOSTICS ROADMAPS

See all diagnostics roadmaps

Cholera diagnostics supply and procurement market shaping roadmap: public summary (2023)

Cholera diagnostic tests are useful for targeting cholera prevention and control measures, including use of oral cholera vaccines (OCV).The Gavi Alliance is working to make fit-for-purpose cholera diagnostic tests available to countries eligible for Gavi new vaccine support in order to make cholera vaccination efforts more effective, efficient, and equitable. This document is the public summary of the market shaping supply and procurement roadmap for cholera diagnostic tests.

Last updated: 12 Jul 2023

Subscribe to our newsletter